Clinical Trials Browser

Phase 1 × INDUSTRY × Antibodies, Bispecific × Clear all

Diabetes Mellitus, Insulin-Dependent, 12, Lethal Congenital Contracture Syndrome 2, Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Multiple Endocrine Neoplasia Type 2a

NCT05293912 2025-03-18

SG2501 Safety Study in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma.

Phase 1 Terminated

2 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Hematologic Neoplasms

NCT05101109 2024-07-31

Study to Evaluate the Safety and Tolerability of ABL501, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL501 in Subjects With Any Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors

Phase 1 Completed

24 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT03030287 2020-09-03

A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer

Phase 1 Completed

44 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02298387 2020-08-11

A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors

Phase 1 Completed

71 enrolled

Other solid neoplasm

Advanced Solid Tumor Malignancies

NCT03035253 2020-08-11

A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer

Phase 1 Terminated

16 enrolled

Gastrointestinal

Colorectal Neoplasms

Clinical Trials

LuCa-MERIT-1

SG2501 Safety Study in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma.

Study to Evaluate the Safety and Tolerability of ABL501, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL501 in Subjects With Any Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors

A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer

A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors

A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer